论文信息 - First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers. - 字舞流文

First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers.

M. Kris | P. Jänne | S. Ou | S. Ou | T. Mok | P. Janne | Dong-Wan Kim | I. Taylor | R. Martins | S. Letrent | Hui Zhang | Z. Goldberg | H. Zhang